Journal ArticleDOI
Influence of disease on binding of drugs to plasma proteins.
Reads0
Chats0
TLDR
If drug binding is altered by a disease, the usual value for therapeutic plasma concentration would have to be modified for the usual therapeutic concentration of drug in plasma water to be achieved.Abstract:
The idea of a “therapeutic plasma concentration” of a drug is becoming increasingly important in regulating therapy. One problem in interpreting measurements of plasma concentrations of drugs is the evaluation of potential changes in protein binding caused by disease. Although the intensity of a drug’s action is believed to be related to its concentration in plasma water, our present analytical techniques measure this amount plus the drug bound to plasma proteins. Therefore, if drug binding is altered by a disease, the usual value for therapeutic plasma concentration would have to be modified for the usual therapeutic concentration of drug in plasma water to be achieved.read more
Citations
More filters
Journal ArticleDOI
Binding of Drugs to Serum Albumin
Jan Koch-Weser,Edward M. Sellers +1 more
TL;DR: Most drugs are carried from their sites of absorption to their Sites of action and elimination by the circulating blood, but many others are partly a part of serum water.
Journal ArticleDOI
Plasma and Tissue Protein Binding of Drugs in Pharmacokinetics
William J. Jusko,Mark Gretch +1 more
Journal ArticleDOI
Disease-induced Changes in the Plasma Binding of Basic Drugs
TL;DR: Plasma concentration monitoring of drug therapy by use of total drug concentrations will be inaccurate in situations in which large variations in binding occur, and misinterpretations of both therapeutic monitoring and pharmacokinetic studies in disease slates with altered binding are likely.
Journal ArticleDOI
Protein Binding and Kinetics of Drugs in Liver Diseases
TL;DR: The efficiency with which a drug is metabolised by the liver, the extent of binding to blood constituents, and the aetiology and stage of the hepatic disorder are each important in determining whether significant alterations in drug disposition will occur.
References
More filters
Journal ArticleDOI
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.
TL;DR: The binding of DPH by plasma proteins from azotemic patients appears to be decreased, probably owing to a change in the binding proteins.
Journal ArticleDOI
Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.
TL;DR: Plasma protein binding of diphenylhydantoin (DPH) in normal plasma was investigated with an ultrafiltration technique (at room temperature) with the use of 14C‐labeled DPH with no marked difference between sexes or individuals.
Journal ArticleDOI
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.
D.W. Shoeman,D.L. Azarnoff +1 more
TL;DR: Digitoxin was 86% bound to plasma from uremic patients while plasma from healthy volunteers bound 90%.
Journal ArticleDOI
Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia.
TL;DR: It is postulated that low serum-albumin reduces the number of binding sites for the drug clofibrate, and this was responsible for its toxic effects in patients with hyperlipoproteinaemia secondary to the nephrotic syndrome.
Related Papers (5)
The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.
D.W. Shoeman,D.L. Azarnoff +1 more